Bionano Genomics Stock Revenue
| BNGO Stock | USD 0.26 0.02 8.33% |
Bionano Genomics fundamentals help investors to digest information that contributes to Bionano Genomics' financial success or failures. It also enables traders to predict the movement of Bionano Stock. The fundamental analysis module provides a way to measure Bionano Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bionano Genomics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 36.1 M | 37.9 M |
Bionano | Revenue |
Bionano Genomics Company Revenue Analysis
Bionano Genomics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Bionano Genomics Revenue | 36.12 M |
Most of Bionano Genomics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bionano Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Bionano
Projected quarterly revenue analysis of Bionano Genomics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Bionano Genomics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Bionano Genomics' stock price.
Bionano Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Bionano Genomics is extremely important. It helps to project a fair market value of Bionano Stock properly, considering its historical fundamentals such as Revenue. Since Bionano Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bionano Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bionano Genomics' interrelated accounts and indicators.
| 0.69 | 0.71 | -0.07 | -0.74 | -0.76 | ||
| 0.69 | 1.0 | -0.5 | -0.56 | -0.84 | ||
| 0.71 | 1.0 | -0.52 | -0.57 | -0.83 | ||
| -0.07 | -0.5 | -0.52 | 0.29 | 0.21 | ||
| -0.74 | -0.56 | -0.57 | 0.29 | 0.73 | ||
| -0.76 | -0.84 | -0.83 | 0.21 | 0.73 |
Click cells to compare fundamentals
Bionano Revenue Historical Pattern
Today, most investors in Bionano Genomics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bionano Genomics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bionano Genomics revenue as a starting point in their analysis.
Bionano Genomics Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Bionano Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Bionano Genomics reported 36.12 M of revenue. This is 99.53% lower than that of the Life Sciences Tools & Services sector and 98.18% lower than that of the Health Care industry. The revenue for all United States stocks is 99.62% higher than that of the company.
Bionano Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bionano Genomics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bionano Genomics could also be used in its relative valuation, which is a method of valuing Bionano Genomics by comparing valuation metrics of similar companies.Bionano Genomics is currently under evaluation in revenue category among its peers.
Bionano Genomics Institutional Holders
Institutional Holdings refers to the ownership stake in Bionano Genomics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bionano Genomics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bionano Genomics' value.| Shares | Archford Capital Strategies, Llc | 2024-09-30 | 69.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 62.4 K | Jane Street Group Llc | 2024-06-30 | 48.5 K | Susquehanna International Group, Llp | 2024-06-30 | 48.4 K | Inspire Advisors, Llc | 2024-09-30 | 37.3 K | Simplex Trading, Llc | 2024-06-30 | 29.5 K | Justinvest Llc | 2024-06-30 | 29 K | Golden State Equity Partners | 2024-09-30 | 26.5 K | Tower Research Capital Llc | 2024-06-30 | 25.8 K | Vanguard Group Inc | 2024-09-30 | 2.2 M | Geode Capital Management, Llc | 2024-09-30 | 882.9 K |
Bionano Fundamentals
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (2.03) % | ||||
| Current Valuation | 25.57 M | ||||
| Shares Outstanding | 101.99 M | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 12.81 % | ||||
| Number Of Shares Shorted | 12.11 M | ||||
| Price To Earning | (1.80) X | ||||
| Price To Book | 0.53 X | ||||
| Price To Sales | 0.71 X | ||||
| Revenue | 36.12 M | ||||
| Gross Profit | 5.95 M | ||||
| EBITDA | (213.6 M) | ||||
| Net Income | (232.49 M) | ||||
| Cash And Equivalents | 187.34 M | ||||
| Cash Per Share | 0.65 X | ||||
| Total Debt | 79.41 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.75 X | ||||
| Book Value Per Share | 2.10 X | ||||
| Cash Flow From Operations | (125.18 M) | ||||
| Short Ratio | 3.81 X | ||||
| Earnings Per Share | (2.30) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 344 | ||||
| Beta | 2.38 | ||||
| Market Capitalization | 26.07 M | ||||
| Total Asset | 214.4 M | ||||
| Retained Earnings | (581.21 M) | ||||
| Working Capital | 40.09 M | ||||
| Current Asset | 14.39 M | ||||
| Current Liabilities | 8.72 M | ||||
| Net Asset | 214.4 M |
About Bionano Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bionano Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionano Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionano Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bionano Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bionano Stock
| 0.69 | A | Agilent Technologies Sell-off Trend | PairCorr |
| 0.9 | ME | 23Andme Holding Upward Rally | PairCorr |
| 0.84 | VALN | Valneva SE ADR | PairCorr |
Moving against Bionano Stock
| 0.86 | DRUG | Bright Minds Biosciences Trending | PairCorr |
| 0.78 | VCYT | Veracyte | PairCorr |
| 0.72 | VERA | Vera Therapeutics | PairCorr |
| 0.59 | VANI | Vivani Medical | PairCorr |
| 0.54 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Bionano Genomics Piotroski F Score and Bionano Genomics Altman Z Score analysis. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.30) | Revenue Per Share 0.749 | Quarterly Revenue Growth (0.10) | Return On Assets (0.33) | Return On Equity (1.38) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.